Type 2 Diabetes Mellitus
Conditions
Brief summary
Thiazoledinediones decrease blood glucose by their insulin-sensitizing properties. Here the investigators examined whether pioglitazone (PIO) improves insulin sensitivity independently of glycemic control and whether adipokines or non-esterfied fatty acids (NEFA) serve as mediators.
Interventions
DRUGPioglitazone
12 weeks of pioglitazone treatment
Sponsors
German Diabetes Center
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
45 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
* well controlled patients with type 2 diabetes (Hb1Ac \< 8%) * no insulin therapy * no co-morbidities * stable medication use for the last 6 months * stable body weight the last 6 months * no diet in the last 6 months
Exclusion criteria
* Hb1Ac \> 8% * insulin therapy * diabetes-related co-morbidities, like cardiovascular disease, neuropathology * unstable medication use * unstable body weight in the last 6 months (\> 5 kg) * following a diet in the last 6 months
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| whole body insulin sensitivity | within a minimal of 1 week before the start of the 12 weeks pioglitazone or glimepiride treatment and after the last day of the treatment period. | Participants underwent a two-step hyperinsulinemic euglycemic clamp to determine insulin sensitivity, expressed as rate of glucose disposal (Rd) in mg/kg/min. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| intrahepatocellular lipid content | within a minimal of 1 week before the start of the 12 weeks pioglitazone or glimepiride treatment and after the last day of the treatment period. | Liver proton-magnetic resonance spectroscopy was applied to determine liver fat (HCL) in % (relative to the water peak). |
Countries
Austria
Outcome results
None listed